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Abstract 
Background: Mechanical ventilation is an essential therapy to support critically ill 
respiratory failure patients. Current standards of care consist of generalised approaches, 
such as the use of positive end expiratory pressure to inspired oxygen fraction (PEEP–
FiO2) tables, which fail to account for the inter- and intra-patient variability between 
and within patients. The benefits of higher or lower tidal volume, PEEP, and other 
settings are highly debated and no consensus has been reached. Moreover, clinicians 
implicitly account for patient-specific factors such as disease condition and progression 
as they manually titrate ventilator settings. Hence, care is highly variable and poten-
tially often non-optimal. These conditions create a situation that could benefit greatly 
from an engineered approach. The overall goal is a review of ventilation that is acces-
sible to both clinicians and engineers, to bridge the divide between the two fields 
and enable collaboration to improve patient care and outcomes. This review does not 
take the form of a typical systematic review. Instead, it defines the standard terminol-
ogy and introduces key clinical and biomedical measurements before introducing 
the key clinical studies and their influence in clinical practice which in turn flows into 
the needs and requirements around how biomedical engineering research can play a 
role in improving care. Given the significant clinical research to date and its impact on 
this complex area of care, this review thus provides a tutorial introduction around the 
review of the state of the art relevant to a biomedical engineering perspective.
Discussion: This review presents the significant clinical aspects and variables of 
ventilation management, the potential risks associated with suboptimal ventilation 
management, and a review of the major recent attempts to improve ventilation in the 
context of these variables. The unique aspect of this review is a focus on these key ele-
ments relevant to engineering new approaches. In particular, the need for ventilation 
strategies which consider, and directly account for, the significant differences in patient 
condition, disease etiology, and progression within patients is demonstrated with the 
subsequent requirement for optimal ventilation strategies to titrate for patient- and 
time-specific conditions.
Conclusion: Engineered, protective lung strategies that can directly account for and 
manage inter- and intra-patient variability thus offer great potential to improve both 
individual care, as well as cohort clinical outcomes.
Keywords: Mechanical ventilation, Intensive care, Respiratory failure, Model-based 
treatment, Patient-specific ventilation, Protective lung strategies
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Background
In intensive care, mechanical ventilation (MV) is the primary support for patients with 
respiratory failure or acute respiratory distress syndrome (ARDS) despite decades of 
research [1]. MV is an essential life support, but if non-optimally managed, it can also 
degrade patient condition [2, 3]. MV provides positive airway pressure and airflow to 
support work of breathing, sustain oxygenation and enable patient recovery. In particu-
lar, the goal of MV is to provide these supports while protecting the lung from further 
damage [1, 4]. However, while there is some general agreement on which MV settings 
and clinical parameters are preferred [1, 5, 6], there are limited guidelines and conflicting 
trial results [7–13] in optimising MV support, resulting in variable MV settings. (Please 
refer to these recent reviews of clinical advances in treatment [1] and challenges [14] of 
MV for ARDS.) Moreover, MV care and guidelines are almost entirely clinically deter-
mined in contrast to the area of diabetes/metabolism, for example, which has a long his-
tory of mathematical and engineering research that has driven recent advances in care.
An example of highly variable MV settings is the positive end-expiratory pressure 
(PEEP). Some may consider lower PEEP superior and safer [15, 16]. However, lower 
PEEP can lead to increased cases of oxygen desaturation and hypoxemia [8, 17] and 
atelectrauma, indicated by a greater number of rescue therapies and death after rescue 
therapy [13]. In contrast, higher PEEP can increase recruitment of collapsed lung units 
[18–20], stabilising injured or collapsed alveoli [21, 22], reducing inflammatory medi-
ators in plasma and bronchoalveolar lavage fluid [23]. However, higher PEEP can also 
cause ventilator induced lung injury (VILI) [8, 13]. Hence, there is no consensus on the 
best PEEP, which can vary between and within patients.
Optimal settings are patient-specific and likely evolve over time, and are thus not eas-
ily titrated using standard clinical protocols. Because current tools and methods cannot 
provide enough insight into patient-specific response to MV in real-time [24], particu-
larly breath-to-breath or hour-to-hour, and non-invasively, the best approach in setting 
MV remains uncertain [3, 13, 21, 22, 24–27]. As a result, the current standard of MV 
therapy in the intensive care unit (ICU) relies heavily on clinician experience and intui-
tion, or a generalised one size fits all approach, such as setting MV for acute respira-
tory distress syndrome (ARDS) patients using the ARDSNet or lung protective strategies 
recommendations [5, 8, 10, 11]. Therefore, patient-specific MV methods are needed to 
improve individual patient outcomes beyond where they are today [24].
More specifically, the use of biomedical devices and model-based methods enable 
broader and wider perspective on patient-specific condition in setting MV [24]. How-
ever, research in this area is still lacking. Of particular concern, is that MV is a highly 
integrated field, mixing medical knowledge with engineering technologies, including 
control systems, signal processing and mechatronics. As such, technologists and engi-
neers rely heavily on clinical expertise for guidance, potentially without proper under-
standing of the problem, creating a need to bridge this lack of medical knowledge.
This paper addresses this issue via a comprehensive review of the clinical aspects and 
application of MV for readers of both clinical and non-clinical expertise. A fundamental 
introduction to MV is included first to define the clinical terminology used throughout 
and to organize the review, which, despite being medically focused, aims to maximize 
comprehension by non-clinical readers and offer entry points from the engineering 
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perspective to understand the fundamental mechanics at play. In particular, the vari-
ables and mechanics of MV are placed in a structure that is also suitable for engineering 
mechanics analysis, with relevant clinical references on their use.
The article covers the adverse effects of suboptimal MV settings, before discuss-
ing several large clinical randomised controlled trials concerning different MV strate-
gies and recent trends, all of which set the clinical context and better define the clinical 
shortfalls that exist today. The MV strategies presented are classified into families based 
on how they intend to mitigate the challenges of MV. This is a new method of assessing 
the field and translating engineering solutions to medical problems, and vice versa. The 
overall goal is to delineate the clinical state of the art to highlight the need for patient-
specific methods in standardising MV settings, ending with a particular focus on how 
novel engineering, modelling and simulation approaches to measurement, control and/
or management could have significant clinical impact. It thus provides a clinical state 
of the art tutorial review to motivate potential avenues for future engineering science 
research to transform this ubiquitous critical care therapy.
Hence, the overall goal of this review is to provide a broad overview, particularly for 
non-specialists or those new to this area so they can rapidly assimilate the state of the 
art, rather than a detailed, systematic review of a particular facet, clinical or engineering. 
Thus, in this case, the review covers both clinical definitions, to introduce terminology 
and its clinical and engineering meaning, as well as to discuss the clinical state of the art, 
and further provide context for the mechanics and biomedical engineering aspects. As 
a result, some areas may appear overly simplified, to those familiar with that portion of 
the problem, but are necessary for those who are seeking a foothold. Throughout, we will 




Key parameters of MV supported breathing cycles include: tidal volume, airway pres-
sure, peak inspiratory pressure, plateau pressure, positive end-expiratory pressure, frac-
tion of inspired oxygen, respiratory rate and inspiration to expiration ratio.
Tidal volume  (Vt)
Physically,  Vt is the air volume entering and exiting the lungs each breath.  Vt is chosen 
by the clinician, usually using predicted body weight, and for ARDS patients  Vt between 
4 and 8 mL/kg is recommended [28]. Higher tidal volume can assist with removal of car-
bon dioxide from the lung in patients with hypercapnia or delivery of oxygen to patients 
that have hypoxemia. However, excessive volumes can also overinflate and stretch lung 
tissue causing injury [29, 30].
Fraction of inspired oxygen (FiO2)
FiO2 is the oxygen concentration delivered to the patient. Higher  FiO2 enables better 
exchange oxygen from the lungs into the blood, increasing the partial pressure of oxy-
gen in the alveoli and thus the rate of diffusion.  FiO2 above 21% (atmospheric air) is 
often used to increase oxygenation, while avoiding the risks associated with delivering 
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higher pressures and tidal volumes, or when collapsed alveoli are not recruitable [31]. 
However, excessive  O2 partial pressures can cause oxygen toxicity [32, 33].
Airway pressure  (Paw)
The Paw is the pressure supplied from the ventilator to the patient during MV. There 
are four distinct measures of Paw during a typical MV breathing cycle:
• Positive end expiratory pressure (PEEP): PEEP is the elevated airway pressure at 
the end of expiration. PEEP is an important setting used to maintain lung recruit-
ment to allow gas-exchange [34, 35]. It also prevents the cyclic opening and clos-
ing of collapsed lung units (atelectasis), which can cause further damage [2, 30]. 
Titrating PEEP is often a topic of debate, with some advocating higher levels, and 
some lower levels [8]. It is currently most often set using the PEEP–FiO2 table [5].
• Peak inspiratory pressure (PIP): PIP is the maximum airway pressure during inspi-
ration. PIP is limited to avoid excessive pressures causing further injury [2, 36, 37]. 
PIP may be limited in pressure control modes where the pressure range can be set.
• Plateau pressure (Pplat): Plateau pressure is the airway pressure measured during 
an end of inspiratory pause [38]. Compared to PIP, this pressure level is lower, as it 
is not influenced by the dynamic pressure differences due airway resistance. This 
pressure level is used as a representation of the pressure in the alveoli, and is often 
used as a threshold for high-pressure levels. Typically, airway pressure is set at 
pressure level where Pplat is less than 30–35 cmH2O to avoid barotrauma [39].
• Driving pressure (ΔP): ΔP is the pressure difference added above PEEP to Pplat. 
Recent post hoc and meta-analyses have suggested that driving pressure may be 
more important than other MV parameters determining outcomes [40, 41] that 
higher driving pressures are associated with increased mortality [42]. Crucially, 
these results and, any new guidelines, must consider ΔP with respect to at least 
one of PEEP and Pplat.
The four primary Paw measures do not completely define a breath cycle but, as 
described in Fig.  1, do measure the extremes of both inspiration and expiration. 
Together with the time components, this set of metrics can roughly describe the 
entire breathing cycle with only minimal redundancy.
Respiratory rate (RR) and inspiration to expiration (I:E) ratio
The RR during MV is the number of breaths per minute. It is commonly around 
16–20 so that each breath is approximately 3–4  s in length. During fully controlled 
ventilation, within the length of each breath (corresponding to the RR), clinicians can 
adjust the I:E ratio—the ratio of inspiration time to expiration time—to ensure ade-
quate ventilation of carbon dioxide out of the lung. Setting RR together with Vt also 
ensure adequate minute ventilation (litres of air per minute). Spontaneously breath-
ing patients on support modes set RR themselves, and hybrid modes, such as manda-
tory ventilation, ensure a minimum allowable RR is met.
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Ventilation modes
Fundamentally, ventilation can be divided into several groups by the level of invasion, 
the mode used and the target. Typically, MV is first split into invasive or non-invasive, 
determined if the patient is intubated or not, and then subdivided into control or sup-
port modes, depending on the patient’s breathing efforts and sedation, and finally, pres-
sure or volume controlled modes [43–45]. Figure  2 describes three tiers that roughly 
align with the decision-making process to completely define each of the three dimen-
sions. The box representing control mode non-invasive ventilation is shaded to desig-
nate that this combination of settings is rarely employed [45]. Please refer to a recent 
review of ventilation modes and settings in the context of non-invasive ventilation [45].
Fig. 1 An idealized MV breath cycle highlighting common pressure measurements including positive end 
expiratory pressure (PEEP), driving pressure (ΔP), peak inspiratory pressure (PIP), and plateau pressure  (Pplat) 
and the two time components, inspiration (I) and expiration (E), that determine the I:E ratio. These measures 
are the most commonly monitored in practice and employed in modelling and moreover as a set can 
roughly describe both inspiration and expiration
Fig. 2 A simple schematic diagram describing how MV is specified by selecting one option from each 
of three classes. Typically, the type (invasive vs non-invasive) is selected first, then the mode (support/
spontaneous vs control), and finally the target (pressure vs volume). These three dimensions partition the 
possible combinations into six commonly employed sets (omitting non-invasive control ventilation)
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1. Invasive versus non-invasive:
• MV can be delivered invasive or non-invasively. Invasive ventilation involves 
insertion of an endotracheal tube or tracheotomy, whereas non-invasive ven-
tilation (NIV) is delivered via face mask [46]. Invasive ventilation is most 
common when the ventilator is required to manage the entire patient work of 
breathing.
• The application of NIV for ARDS remains controversial. Implementation of NIV 
requires more training of clinical staff [47], remains complicated to correctly iden-
tify ARDS patients that are likely to benefit [48], and NIV failure, leading to intu-
bation, is common [49]. In a recent study of 2800 ARDS patients, 15% received 
NIV and failure rates ranged from 22 to 47% for patients with mild and severe 
ARDS with hospital mortality rates tripling for patients with NIV failure (45% vs 
15% for success) [50]. However, NIV is actively being improved as evidenced by a 
recent study that terminated early for efficacy. The authors compared outcomes of 
ARDS patients treated with NIV delivered by helmet, compared to a typical face 
mask and observed that intubation rates dropped, ventilator free days increased, 
and 90 day mortality rates decreased [51].
2. Control versus support modes:
• Control ventilation modes strictly adhere to the chosen ventilation strategy, and 
are commonly used for patients who are heavily sedated, paralyzed, or cannot 
breathe regularly enough to support themselves. They provide all the work of 
breathing.
• Support ventilation modes act as an assistant to patients who are breathing spon-
taneously. Unlike controlled modes, support MV delivers breathing cycles when 
triggered by patients.
• Currently, hybrid modes, such as synchronized intermittent mandatory ventila-
tion (SIMV), allow patients to control the timing of their breathing, while offering 
up to full support, but also ensure that mandatory breaths are given to the patient 
when no spontaneous effort is made. Hybrid modes ameliorate the limitations of 
set modes.
3. Pressure versus volume control methods:
• Pressure control fundamentally controls the input and output pressure of the ven-
tilation. This mode allows precise limitation of the maximum PIP to prevent baro-
trauma [52]. During pressure control, the airflow and tidal volume are delivered 
depending on the controlled pressure.
• Volume control methods enable a set minimal tidal volume during ventilation. In 
return, the airway pressure is thus determined by the flow and tidal volume pro-
file.
• Similar to control and support modes, hybrids between pressure and volume con-
trol ventilation modes have emerged to provide the advantages of both modes 
[53].
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MV outcome measurements
The quality of MV delivery is often assessed using outcome measurements or surrogates. 
The following are several outcome measurements often assessed.
Blood oxygenation can be measured using arterial blood gas information, partial pres-
sure of oxygen  (PaO2), or using pulse oximetry, peripheral capillary oxygen saturation 
 (SpO2). Blood oxygenation is the most common monitoring metric to ensure ventila-
tion is adequate and delivering sufficient oxygen to the patient. Standard practice aims 
for minimum  PaO2 > 80  mmHg [54, 55] and minimum  SpO2 on the order of 88–95% 
depending on the current  FiO2 [8, 10, 11].
Minute ventilation is the volume of air delivered during 1 min and is effectively the 
product of the RR and  Vt input settings. Target minute ventilation goals are commonly 
8–10 L/min for adults [56, 57].
Transpulmonary pressure is the pressure difference between the alveoli and the pleu-
ral cavity. Airway pressure—the pressure at the airway opening—is easier to measure 
but may not be as clinically informative as transpulmonary (or esophageal) pressure 
[58]. One measured airway pressure may not translate into consistent transpulmonary 
pressures between patients due to the heterogeneity of patient condition [59]. Since the 
mechanics of lung collapse, recruitment and overdistension depend on the pressure 
within the lung, transpulmonary pressures are clearly more relevant to the stress and 
strain applied to the lung and any subsequent injury than measured airway pressure [2, 
60]. For this reason, MV should provide adequate transpulmonary pressure to maintain 
acceptable oxygenation, while minimising both atelectasis and overdistension [2, 27]. 
However, estimated measures of transpulmonary pressure require the use of a highly 
invasive balloon catheter to measure the pleural pressure [27] and are thus not often 
applied clinically. Please refer to a recent review discussing applications of transpulmo-
nary (and esophageal) pressure [58].
Lung imaging techniques create images of the lungs for clinicians to assess lung con-
dition, allowing them to treat the patient based on their observation [24]. Computed 
tomography (CT) is regarded as a gold standard. CT images allow clinicians to assess 
patient condition, response to PEEP titrations, alveoli recruitment/distension and gas 
distributions. However, CT for ICU patients is costly, requires transfer to the radiology 
department or a portable CT machine and further exposes the patient to radiation [24, 
61–65]. Hence, it is not a regular care-monitoring tool.
Portable X-rays remain the most common radiographic examination [64, 65] as they 
can be carried out at the bedside and subject the patient to a smaller radiation dose. 
However, portable radiographs have lower and more variable quality [63, 65] and com-
monly only show one two-dimensional, frontal plane, compared to images in multiple 
planes with varying slice thickness available in CT, helical CT or other three-dimen-
sional techniques [64, 65]. Finally, and most importantly, imaging methods that use ion-
ising radiation are not suitable for continuous or semi-continuous monitoring of lung 
condition. Thus, the application of such imaging techniques to guide therapy remains 
limited [66].
An emerging form of lung imaging is electrical impedance tomography (EIT). EIT has 
shown good correlation with CT, such that it has been proposed and recently validated 
to guide ventilation therapy [67–69]. Commercial EIT systems generate lung images 
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using relative impedance changes with respect to end-expiration, allowing ventilation 
recruitment and inhomogeneity to be monitored in real-time [68, 70]. Several recent 
studies have demonstrated the utility of EIT at the bedside by titrating PEEP to ensure 
protective lung strategies balance recruitment without overdistension [71–73]. Moreo-
ver, EIT has shown good correlation with CT [74] but is not yet ready to replace CT 
as a gold standard as the technology is relatively new and costly [75]. A recent review 
described EIT as clinically validated but noted the literature lacks evidence to its efficacy 
in clinical outcomes [69]. More studies are thus required for this technology to imple-
ment EIT as part of regular patient care. Please refer to these recent reviews for further 
reading in the clinical [69, 70] and bioengineering [76] state of the art.
Other examples of outcome measurements that can quantify the quality of care for 
mechanically ventilated patients in the ICU include:
• Length of mechanical ventilation (LoMV) and/or ventilation free days (VFD): LoMV 
is quantified as how long the patient requires mechanical ventilation support and 
VFD is measured as the number of days free from ventilator support within a 28-day 
period.
• Mortality: Measured as survived or deceased within a time-period. Common exam-
ples are ICU mortality, hospital mortality, 28-day mortality, and 90-day mortality,
• Severity scoring systems: Patient severity scores and metrics are used to account for 
the severity of the patient’s disease state. Several common examples are the Acute 
Physiology and Chronic Health Evaluation score (APACHE) [77–79], Simplified 
Acute Physiology Score (SAPS) [80, 81], and Sequential Organ Failure Assessment 
score (SOFA) [82].
Summary
ICU MV treatment is managed by setting several basic ventilation parameters, while 
checking that other measured parameters are within acceptable bounds. This process is 
further complicated while intermittently making small changes to care based on patient 
response. It is common to titrate the ventilation parameters manually to ensure all tar-
gets are met, while trying to reduce the risk of further injury. The lack of clear consen-
sus combined with the wealth of MV modes and settings ensures significant inter- and 
intra-patient variability in care.
The problem with MV management
Ventilation induced lung injury (VILI)
MV is a crucial support for patients with respiratory failure. However, this essential 
treatment can have (unintended) harmful consequences, causing further injury and/or 
delay to recovery. Ventilator induced lung injury (VILI) is caused by non-optimal MV 
and manifests as a mechanical injury to alveoli that exacerbates the systemic inflamma-
tion [23, 30, 70, 83–91]. It can thus directly increase the risk of death [88], as well as 
length and cost of ventilation treatment [92].
A normal, healthy person creates a negative-pressure inside the lung by expanding 
the chest wall and contracting the diaphragm, which creates a negative pressure in the 
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pleural cavity, and in the lung itself. When the pressure inside the lung is lower than 
ambient, air flows into the lung. During expiration, air is exhaled passively, reducing 
the volume of the lung. Modern MV is comprised of positive-pressure ventilation that 
drives air and oxygen into the lung during inspiration and lets expiration occur passively. 
This non-physiological inspiration during MV support, may add stress and strain to lung 
tissues, resulting in trauma in any of four categories: barotrauma, volutrauma, atelec-
trauma, and biotrauma or other [2, 93, 94]. For further discussion on the pathophysiol-
ogy of VILI and several approaches to minimize VILI, please refer to a review by Fan 
et al. [95].
Barotrauma is injury caused by excessive pressures in the lung. The pressure gradi-
ent between the alveoli and the abdomen can cause air to migrate into the interstitial 
tissue causing many of the manifestations of barotrauma [2, 29]. Early work by Peter-
son et al. [36] reported that all patients with PEEP > 40 and/or PIP > 100 cmH2O devel-
oped barotrauma. However, more recently, Weg et al. [96] cast doubt on these results 
when they compared patients with matching disease states (ARDS induced by sepsis) 
and reported no significant difference in pneumothorax rates for high pressures or vol-
umes. Thus, the pressure at incidence is likely patient-specific [97]. Overall, barotrauma 
is a result of driving pressure and/or PEEP that is too high, resulting in excessive PIP and 
lung pressures.
Volutrauma occurs when ventilation with excessive volume stretches the lung tissue 
beyond its elastic limit causing injury. It can lead to pulmonary edema, increased fluid 
filtration, diffuse damage to alveoli, epithelial and microvascular permeability [2, 29]. It 
is a result of too large tidal volume either by specification or as a result of delivered driv-
ing pressure in pressure controlled modes resulting in too much volume expansion.
Atelectrauma is a lung injury that occurs when ventilation with too little volume and/
or pressure causes repeated, cyclic opening and closing of unstable alveoli near the 
boundary of collapsed and aerated areas [1, 94, 98]. MV uses PEEP and higher airway 
pressures to recruit alveoli during inspiration. As the pressure drops during expiration, 
some diseased alveoli collapse and reopen in the next breath. This cyclic opening and 
closing is a symptom of a PEEP that may be too low to keep such recruited alveoli open. 
Atelectrauma is common in patients diagnosed with ARDS and may be more significant 
than originally thought [10]. Hence, patient-specific pressure and PEEP is critical.
Biotrauma is lung injury caused by the body’s response to the invasion of MV and is 
the most difficult lung injury to quantify in a clinical setting. MV can cause increases 
in alveolar-capillary permeability, surfactant inactivation and the release of inflamma-
tory mediators [99–101]. Slutsky et al. [102] and Murphy et al. [103], noted that it can 
lead to multiple organ failure. Non-protective ventilation strategies (e.g.  Vt ~ 12 mL/kg 
and PEEP = 0 cmH2O) are associated with bacterial translocation and the transmission 
of pulmonary infections and inflammatory mediators into the circulatory system with 
subsequent systemic inflammation, compared to protective ventilation strategies with 
moderate PEEP (10–12.5 cmH2O) and lower tidal volume ventilation (~ 5 mL/kg).
Other similar adverse effects of MV include ventilator associated pneumonia [1, 104], 
pulmonary edema or fluid build-up in the lung [8, 70], circulatory depression or a reduc-
tion in cardiac output due to increased chest cavity pressures with PEEP [8], oxygen tox-
icity due to excessive oxygen from  FiO2 [1, 2, 101], and hypercapnia or excessive  CO2 
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caused by too little removal of  CO2 out of the blood [1]. All of these effects increase the 
risk of poor patient outcome.
Patient intra‑ inter variability: disease state and variable treatment response
The lung of a respiratory failure patient is very heterogeneous [70], with mixed healthy 
and diseased alveoli, displaying significant inter- and intra-patient variability. Thus, what 
works for one patient may lead to VILI in another [21, 105]. Equally, what helps some 
diseased alveoli, such as added pressure, may injure nearby healthy alveoli. The inability 
to easily assess lung heterogeneity regularly with imaging, or to selectively provide pres-
sure and volume to areas of the lung thus leads to most of the difficulty in optimising 
care.
Variability between patients (inter-patient) can be driven by heterogeneous disease 
and response to treatment [1]. Within a cohort of ARDS or respiratory failure patients, 
the primary diagnosis is often not recorded as ARDS [106, 107], as the etiology of res-
piratory failure varies with each patient [108, 109], and ARDS may never be diagnosed, 
limited by clinical interpretation of chest imaging (please refer to a recent review for 
discussion surrounding the diagnostic limitations of ARDS [1]). ARDS may be caused by 
both pulmonary and extra-pulmonary insults [1], which has lead to very diverse ARDS, 
or respiratory failure, study cohorts [108, 109]. With the diverse causes of respiratory 
failure comes a wide distribution of lung condition and thus individual patient-specific 
requirements in optimal ventilation settings.
Disease progression and treatment can affect lung condition and the corresponding 
optimal ventilation parameters creating variability within one patient (intra-patient) 
over time. Hence, care must be able to measure appropriate metrics of patient-specific 
lung condition to evolve over time, as well as trying to ensure care is as optimal as pos-
sible at each time point in real-time, rather than intermittently every 6 or 24 h.
Heterogeneity within a patient’s lungs can also lead to variability within one patient 
(intra-patient) during any one breath. Within the ARDS or respiratory failure lung, it is 
common for some areas to be collapsed (atelectasis) and poorly perfused, while others 
are normal. MV cannot provide ventilation separately to the heterogeneous lung areas, 
though one lung ventilation is possible [110]. Considering both lungs, each with signif-
icant variability, selection of ‘optimal’ ventilation settings for overall lung recruitment 
can provide excessive pressures/volumes to some regions, and too little to others. Lung 
injury can thus be exacerbated by attempting to provide improved care by further injur-
ing non-aerated, collapsed alveoli. The result is a need to balance, as discussed, the care 
of injured lung units with the possible harm to unaffected units.
The influence of the definition and diagnosis of respiratory failure patients
Various pulmonary and extra-pulmonary insults may lead to a patient developing res-
piratory failure, or the more severe ARDS [1]. The most frequent are pneumonia and 
extra-pulmonary sepsis [111–113]. The high mortality and morbidity of ARDS patients 
has made these cohorts a focus of MV research, and optimised MV is critical to outcome 
[5, 10, 114].
In 1994, the American-European Consensus Conference (AECC) defined acute 
lung injury (ALI) and ARDS [115] as a syndrome of acute onset of respiratory failure 
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with findings of bilateral infiltrates on chest radiograph. This definition is followed 
by the absence of elevated left heart filling pressure determined either diagnosti-
cally with a pulmonary artery catheter (pulmonary artery occlusion pressure (PaO2) 
of < 18  mmHg) or clinically (absence of evidence of left arterial hypertension) [115, 
116]. A PaO2/FiO2 (P/F) ratio less than 300  mmHg is considered ALI, and P/F 
ratio < 200 mmHg is categorised acute respiratory distress syndrome (ARDS).
This definition was updated in 2012, and is referred to as the ARDS Berlin definition 
[109]. The changes in definition includes: (1) the replacement of ALI with mild, mod-
erate and severe ARDS; (2) PEEP settings; (3) defining the period of acute onset; (4) 
recognition of CT imaging as diagnostic; and (5) exclusion of hydrostatic pulmonary 
edema [117]. The new definition is able to better capture the syndrome, but studies 
have suggested further improvements can be made [118–120].
Following the AECC and Berlin definitions, chest imaging is often performed before 
a final diagnosis is made. Imaging can delay diagnosis and intervention as well as 
add subjectivity by interpreting imaging results [1]. In particular, to provide prompt 
recruitment and maintenance, a recruitment manoeuvre should be performed as 
soon as possible for any MV patient to open up the lung and assist with gas exchange 
[19, 20]. Final diagnosis should then follow patient stabilization.
Equally importantly, ARDS is typically diagnosed at one moment in time near the 
start of ventilation [121]. However, current MV settings, such as PEEP, at that time 
can greatly affect both the measured  PaO2 and the required  FiO2 for adequate oxy-
genation. Estenssoro et al. [121] reported that PEEP > 0 during initial ventilation can 
improve  PaO2 so drastically that ARDS may be misdiagnosed if assessment is delayed 
too long, due to delay in blood gas extraction or waiting for chest imaging results. 
If each patient had been evaluated 6  h later, 52% would no longer fulfil the AECC 
definition for ARDS (P/F < 200) and instead be diagnosed with less severe ARDS or 
ALI [121], possibly changing their overall treatment and care. In this specific study, 
no RMs were performed, and Estenssoro et  al. attributed the improvement in P/F 
ratio from < 200 to > 200 over 24 h for 18 of the 48 similarly ventilated patients to a 
relatively higher mean PEEP of 12.8 cmH2O after 24 h. Thus, initial care choices can 
interact significantly with the diagnosis made and thus, the subsequent care provided.
Villar et al. [122] conducted a similar trial to Estenssoro et al., where patients were 
tracked. Approximately 40% of ARDS patients exhibited an increase in P/F ratio 
to above the AECC threshold when evaluated after 24  h at PEEP ≥ 10  cmH2O and 
 FiO2 ≥ 50%. Villar et al. [123] warns that all respiratory failure patients start off with 
poor oxygenation and neither the AECC or Berlin definitions allows for re-evaluation 
of hypoxemia at consistent ventilator settings, especially PEEP and  FiO2. The authors 
recommend use of a PEEP–FiO2 trial conducted 24 h after ARDS diagnosis, stating 
this test would provide an easy and simple strategy to identify subpopulations and 
provide care based on actual patient risk [123].
Hence, defining and diagnosing ARDS/ALI within respiratory failure is an impor-
tant step towards distinguishing between severe and moderate respiratory failure 
[118], and thus to providing appropriate care. However, the diagnosis of ARDS is slow 
and followed by rapid patient evolution. Care must thus be taken not to misdiagnose 
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patients at the wrong time, or equally, to ensure that the diagnostic process does not 
lead to an inadequate level of care.
What is needed, is a consistent standard of care to provide early ventilation support 
for all patients requiring respiratory support so that patients could be diagnosed when 
convenient. Such an approach, if patient-specific, would allow early action in a consist-
ent framework that does not currently exist in the field. These results thus also clearly 
show the need for patient-specific MV that can evolve as dynamically as the patient in 
the first 24–48 h.
Summary
Mechanical ventilation management must carefully balance a diverse range of different 
ventilator settings. Insufficient or excessive support results in potential harm to patients, 
prolonging their dependency on MV. This issue is exacerbated by inter-patient variabil-
ity in response across cohorts, as well as by intra-patient variability in the evolution of 
condition. There is thus a strong need for optimal titration mechanisms that are patient-
specific, specific to disease state, and can evolve dynamically, in real-time in response to 
patient condition.
MV strategies and clinical trials
There have been numerous ventilation strategies aimed at improving the quality of MV 
and patient outcomes [124]. Please refer to a recent review of the clinical advances for 
treatment of ARDS [1].
Lung recruitment strategies: recruitment manoeuvres
Recruitment as defined by Fan et al. [113], is the “dynamic process of reopening unsta‑
ble airless alveoli through an intentional transient increase in transpulmonary pressure”. 
Recruitment manoeuvres (RM) have shown to promote alveolar recruitment, increase 
end-expiratory volume, improve gas exchange, and attenuate VILI by preventing atelec-
trauma [113]. The tidal cycle during a RM shifts to where cyclic derecruitment is less 
likely to occur given that PEEP is greater than the closing pressure of the majority of 
alveoli. Early in the disease, atelectasis is reversible and the lung may be easily recruita-
ble without negative side effects [125].
By transiently increasing pressure in the lung, collapsed or non-aerated alveoli have 
time to open and recruit. Alveolar recruitment increases the aerated lung volume aiding 
gas exchange and perfusion. The clinical benefits of RMs, particularly early in care, are 
numerous. However, the efficacy of RMs also degrade over time as the lung settles into a 
collapsed state and is thus again, more difficult to recruit [39, 126].
Evidence also suggests that high pressure RMs may overinflate parts of the heterogene-
ous ARDS or respiratory failure lung [127], and temporarily cause circulatory depression 
[128]. The links between respiratory failure severity, recruitability and other outcome 
measurements thus require further investigation and are not standardised, largely as a 
result of not being able to directly determine their impact on lung condition as they are 
conducted.
Rose et  al. [3] described how effective RMs are difficult to conduct due to the het-
erogeneity of each patient and their response to increases of pressure. Specifically, for a 
Page 13 of 31Major et al. BioMed Eng OnLine          (2018) 17:169 
given RM, some may over-distend and others fail to recruit [129], as lung elastance, the 
patient-specific response to pressure and volume varies. Thus, different types of RMs 
have been studied with inspiratory pressures anywhere between 30 and 60 cmH2O [19]. 
Sustained inflations or breath holding sessions for up to 40  s, intermittent sighs with 
high pressure or volume, and incremental increases in PEEP and/or PIP are also com-
mon types of RM. The goal in each case is to manage lung pressure to recruit more lung 
units without damaging others.
However, trials testing RMs have failed to produce consistent results and the best 
recruitment method is yet to be confirmed [113, 130]. Equally, some researchers have 
reported that not all patients benefit from an RM [17] or have any recruitable lung vol-
ume [121]. One recent meta-analysis [131] identified only 10 RCTs evaluating RMs and 
concluded that RMs decrease ICU mortality without increasing risk of barotrauma but 
found no effect on hospital or 28-day mortality. A second meta-analysis [132] reported 
a reduction in mortality pooling 6 RCTs as well as improved oxygenation and fewer res-
cue therapies. The authors of both meta-analyses noted the drastic differences between 
study designs and the prevalence of co-interventions (which together resemble the open 
lung approach) in the majority of the trials that may have confounded assessment of 
the effect of RMs. Thus, there remains a lack of confirmation of the long-term manage-
ment, adverse effects, and generality of these findings in non-selected populations, fur-
ther indicating a need for a patient-specific rather than cohort-specific, approach. Please 
refer to this recent review, and meta-analysis, of RMs [132].
Setting MV using maximum compliance, inflection points
Static compliance has been reported to change significantly with both tidal volume and 
PEEP [133–136]. The local maxima of compliance at a patient-specific PEEP was noted 
to be dependent on the ventilated tidal volume and explained in terms of position on the 
static pressure–volume (PV) curve [133–136]. In general, higher tidal volumes reduce 
the PEEP of maximum compliance [133–136], and equally, higher PEEP at a fixed tidal 
volume can have a similar effect [105].
The gold-standard approach to obtain a static PV curve is the super syringe method 
that quasi-statically fills the lung before emptying it in a controlled stepwise manner 
allowing equilibrium in between each step. The points are connected to form the sig-
moidal static PV curve. The produced loop can be used to optimise PEEP and tidal vol-
ume. Specifically, PEEP can be set in between the lower inflection point (LIP) and upper 
inflection point (UIP) of the static PV curve.
The super syringe method is clinically cumbersome and high workload for clini-
cal staff, as it requires detachment from the ventilator [137, 138] for up to 15 min [24]. 
Static PV curves can be obtained directly from some modern ventilators, but require the 
patients to be sedated and thus are still a significant interruption to care [24]. Hence, 
these curves are not typically or regularly assessed for clinical use.
Stahl et al. [139] described the potential in monitoring dynamic respiratory mechanics 
over incremental PEEP, such as a staircase RM, to estimate both mechanics and recruit-
ment simultaneously. They reported that dynamic respiratory mechanics could be used 
as a diagnostic tool and would be more appropriate than using static mechanics. Com-
paring static and dynamic compliance, Stahl et  al. reported that dynamic compliance 
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was less than static compliance, but the difference was dependent on alveolar pressure 
[139].
Overall, static compliance neglects airway resistance and misrepresents lung dynamics 
by assuming a static or quasi-static condition, when regular MV breathing is dynamic. 
Monitoring dynamic compliance results in smaller compliance (higher elastance) val-
ues, indicating the significance of dynamic effects. It is possible to track breath-to-breath 
dynamic compliance (or elastance) over incremental PEEP [140, 141]. Thus, tracking 
dynamic compliance or elastance as a surrogate of lung condition can be used to quan-
tify recruitment and guide care [24].
Of note, the use of the term static compliance or dynamic compliance are interchanged 
between studies [142]. Definitions in medical texts [44, 57], may be different from other 
studies [129, 139, 143]. Thus, it is important to be clear on the concept and application of 
each definition and method, to avoid misinterpretation of these findings.
Lung protective strategies
As a result of the difficult trade-offs between benefit and risk of MV, the goals of MV 
have changed over the last two decades. In particular, from specifying oxygenation goals, 
to a more cautious approach focusing on minimising VILI, while maintaining acceptable 
ventilation [101]. Avoiding atelectasis and overdistention of alveoli can attenuate alveo-
lar and systematic inflammatory responses [22] and should translate into a measureable 
improvement in ARDS/ALI patient outcomes [2]. Hence, protection or risk mitigation 
has become a primary treatment endpoint.
A protective ventilation strategy is one aiming to minimise VILI and find a balance 
between oxygenation and  CO2 elimination targets. Rose et al. [3] described the “mortal‑
ity reducing effect of lung protective ventilation using low tidal volumes and pressure limi‑
tation” to prevent alveolar collapse or overdistention in ARDS patients. The study also 
suggested that these strategies might also be beneficial in patients with normal lungs. 
The following sections summarise several lung protective strategies examined.
The ARDS network trial
The ARDSNet strategy aims to minimise distension-induced lung injury, while main-
taining acceptable oxygenation, by ventilating with small tidal volumes (≤ 6 mL/kg) and 
plateau pressures lower than 30 cmH2O [26]. The ARDSNet trial showed that lower tidal 
volumes (6.2 ± 0.8 mL/kg) are better than higher (11.8 ± 0.8 mL/kg). This low  Vt strat-
egy uses tables of fixed combinations of  FiO2 and PEEP that are periodically adjusted to 
maintain oxygenation goals [26]. ARDSNet is easy to follow, but relies on the relation-
ship between  PaO2 and  FiO2 being generic to all patients at all times as their condition 
evolves.
However, the physiological rationale and the ‘one size fits all’ lack of individuality 
in care has been questioned [26]. The ARDSNet protocol may also be associated with 
increased atelectasis due to the low PEEP used and lack of RMs [26]. Thus, to avoid VILI 
by minimising lung strain and further improving care, the ideal tidal volume should be 
monitored in a patient-specific breath-by-breath or high time resolution approach simi-
lar to PEEP [24].
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The open lung approach
The open lung approach (OLA) aims to open and maintain lung recruitment [1]. 
It also reduces dynamic strain [26]. RMs are used to open up the lung and PEEP is 
titrated to gas exchange or respiratory variables to maintain recruitment, avoiding 
cyclic collapse/re-opening [26].
Cohort based OLA approaches using PEEP–FiO2 tables or oxygen saturation goals Three 
significant, early clinical trials of OLA strategies are ALVEOLI [8], LOVS [10], and 
EXPRESS [11]. ALVEOLI used two predetermined PEEP–FiO2 tables to ensure  SpO2 
was within acceptable limits of 88–95% [8]. The lower PEEP group represented clini-
cal consensus in 1995, whereas the higher PEEP group reflected the beneficial results of 
Amato et al. [7]. ALVEOLI used a target  Vt of 6 mL/kg predicted body weight with PIP 
limited to 30 cmH2O or less. LOVS [10] also utilised PEEP–FiO2 tables with  Vt of 6 mL/
kg, but conducted a 40 s breath-hold at 40 cmH2O with  FiO2 of 1.0 and thus allowed PIP 
up to 40 cmH2O. EXPRESS [11] took a different approach by adjusting  FiO2 to maintain 
oxygenation goals for the participants in the ‘minimal distension’ control group. PEEP 
and PIP were kept as low as possible without dropping out of an acceptable oxygenation 
range. Within the increased recruitment group, PEEP was kept as high as possible pre-
venting PIP rising above 30 cmH2O regardless of the effect on oxygenation.
None of these three large multi-centre trials conclusively reported any benefit of 
the OLA or higher PEEP ventilation. However, EXPRESS did report a significant 
improvement in ventilator free-days (median [IQR]: 7 [0–19] vs 3 [0–17], p = 0.04). 
Although the primary outcome of mortality failed to reach significance, benefits 
including higher compliance values, improved oxygenation [8, 11], and reduced rates 
of, and death from, refractory hypoxemia [10], were achieved.
OLA approaches using PEEP based on static pressure–volume curves An early, small 
trial by Amato et al. [7] reported a benefit from higher PEEP ventilation above the LIP 
on a PV curve compared to standard ventilation. Mortality was reduced from 71 to 
38% and rates of barotrauma were greatly reduced (n = 53, p < 0.001). Villar et al. [9] 
conducted a similar trial, setting PEEP 2 cmH2O higher than the LIP and reported sig-
nificant improvements in ICU and hospital mortality, ventilator free days, and organ 
failures (n = 95). However, Oba et al. [12] argued that the static pressure–volume curve 
may not be the best way to select optimal PEEP for an OLA.
OLA approaches using PEEP based on dynamic compliance/elastance Spieth et al. [26] 
conducted an animal trial involving pigs with surfactant washout induced ARDS, ran-
domised into either the standard ARDSNet protocol (PEEP = 12 cmH2O) or an open lung 
approach (OLA) with PEEP set to minimal respiratory elastance. PEEP and mean airway 
pressure were higher in the OLA. OLA was associated with improved oxygenation after 
6 h and redistributed pulmonary perfusion, but with more alveolar overdistension, while 
ARDSNet was associated with more intra-alveolar haemorrhage. Inflammatory media-
tors and markers of lung parenchymal stress did not differ significantly. Better redistribu-
tion of pulmonary blood flow in the OLA approach may contribute to better ventilation-
perfusion matching and the reported improved oxygenation.
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Another, more recent, animal study by Santos et  al. [144] compared the pulmonary 
vascular mechanics of three groups each with PEEP set based on the maximal com-
pliance PEEP, (1) hyperinflation = 6  cmH2O above, (2) OLA = 2  cmH2O above, and 
(3) collapse = 6 cmH2O below. The OLA group displayed the lowest pulmonary artery 
resistance, effective arterial elastance, and reflection coefficient. The authors concluded 
that OLA was the best setting. Therefore, a patient-specific OLA strategy providing 
PEEP corresponding to minimal elastance (or maximal compliance) is beneficial in 
pigs, but remains untested against clinical outcomes in a randomized controlled trial in 
humans.
There are two recent studies that have shown promising results of the OLA. First, 
a multicenter RCT, by the Open Lung Approach Network [145], screen 1874 patients 
under ‘standardized ventilator settings’  (FiO2 ≥ 0.5, PEEP ≥ 10  cmH2O) and included 
patients with ARDS (P/F ratio ≤ 200  mmHg) into either a control ARDSNet group 
(n = 101, PEEP set by the ARDSNet protocol [5]) or a OLA group (n = 99, PEEP = PEEP 
at maximal dynamic compliance). Both airway driving pressure and P/F ratio improved 
significantly at 24, 48, and 72  h for the OLA group as compared to ARDSNet group. 
Although the study was statistically underpowered to significantly show reductions in 
mortality, a non-significant trend of lower mortality was observed (60 day: 29% vs 33%, 
p = 0.18; ICU 25% vs 30%, p = 0.53). Ventilator-free days were similar in both groups (8 
[0–20] vs 7 [0–20], p = 0.53). The Open Lung Approach Network concluded that OLA 
improves oxygenation and driving pressure without detrimental effects, which supports 
a larger multicenter OLA trial. The careful design of performing patient screening under 
standardized conditions ensures that inclusion is not biased by the current ventilator 
settings that are known to affect P/F ratio and subsequent ARDS diagnosis [121, 122].
The second study also examined the effect of OLA but instead in a cohort of major 
abdominal surgery patients [146]. Patients were assessed after a 30-min period of stand-
ardized ventilation  (Vt = 6 mL/kg, PEEP = 5 cmH2O) and subjected to a RM after which 
each patient was randomized into either a control group (n = 18, PEEP = 5 cmH2O), or 
an individualized open-lung PEEP group (n = 18, PEEP = PEEP at maximal dynamic 
compliance). Compared to the condition prior to the RM, the OLA group displayed 
an improvement in both: (1) an increase in compliance and (2) a decrease in driving 
pressure, whereas the control group did not. Despite being performed in anesthetized 
healthy individuals, opposed to ARDS patients, this study further validates the intuition 
behind the OLA, RMs and individualized PEEP settings.
Overall, different studies of OLA strategies have shown modest clinical benefits. How-
ever, improvements in primary patient outcomes have not yet been fully established by 
large multi-centre trials [7–11, 145]. Again, the lack of a patient-specific approach is a 
potential limiting factor that could impede some of these studies. The more recent OLA 
results [145–147] point towards a patient-specific compliance/elastance as a means of 
obtaining the best benefits of an OLA approach.
Variable ventilation strategies
Healthy physiological systems exhibit a natural variability that leads to greater flexibility 
and more robust function compared to diseased systems. In contrast, a low variability 
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breathing pattern may be observed in MV patients who failed to wean from MV. Thus, it 
has been proposed to reintroduce variability to replicate this behaviour [148].
Variable controlled ventilation has been associated with improved oxygenation, a 
reduction in mean peak airway pressure, as well as improved pulmonary function in 
several animal studies [149–153]. The best results occur when tidal volume variabil-
ity matches the variability in healthy subjects [154]. The mechanisms responsible may 
include recruitment, surfactant release and improved volume/flow matching because of 
the redistribution of pulmonary blood flow [151, 152]. It is hypothesized that variable 
tidal volumes improve pulmonary function by replicating natural variability.
Neurally adjusted ventilation assist mode (NAVA) [155], is an assist ventilation mode 
that uses patient diaphragm electrical activity, Eadi, to trigger and cycle off the venti-
lator support. It also uniquely delivers airway pressure in proportion to this measured 
Eadi, matching ventilator support with patient’s demand. NAVA was found to improve 
patient-ventilator interaction, reducing the number of asynchrony events [156], as 
well as increasing respiratory variability in Vt and flow related variables [157]. Studies 
on NAVA have reported on impact to the patients [158–160], and an optimal titration 
method [161, 162]. Thus, the benefits of this approach are potentially more substantial 
for patients ventilated for long durations. However, similar to other ventilation strate-
gies, there is also limited guideline is setting the appropriate NAVA level [161–163] of 
pressure support, so its use is affected by this difficulty and its added cost.
High frequency oscillatory ventilation (HFOV) and airway pressure release ventilation 
(APRV)
In both these approaches, a relatively high mean airway pressure, referred to as ‘con-
tinuous distending pressure’ in HFOV or ‘Phigh’ in APRV, is used to maintain a healthy to 
high end-expiratory lung volume and adequate oxygenation levels. Both methods pro-
mote alveolar recruitment and maintenance due to the continuously elevated pressure 
within the lung, and minimising atelectasis as the minimum pressure is relatively high. 
Recruitment not only depends on the pressure in the lung, but also the duration that 
pressure is held, where elevated pressures for a relatively long time can assist with open-
ing more stubborn, stiffer alveoli.
HFOV ventilation uses rapid application of small tidal volume breaths with a large 
mean airway pressure to ensure adequate oxygenation [101, 164, 165]. However, due to 
the small tidal volume breaths, the patient’s lung has a large proportion of dead space 
and reduced alveolar minute ventilation with less  CO2 clearance. The majority of HFOV 
studies treated neonatal patients and reported small reductions in chronic lung disease 
[101]. Recent studies to compare HFOV with conventional MV have reported prom-
ising physiological and inflammatory results [101, 165] but others have reported no 
effect on patient outcomes [166]. Moreover, recent guidelines [28] considering six RCTs 
strongly recommend that HFOV should not be routinely used in moderate-severe ARDS 
patients. The deleterious effects of HFOV, observed in some studies, may be attributed 
to higher airway pressures causing negative hemodynamic consequences [1].
APRV is similar to HFOV, but includes brief periods where the pressure is dropped 
to release air from the lungs and eliminate  CO2. These pressure releases must be kept 
brief to prevent the pressure dropping to a point where the alveoli may start to collapse. 
Page 18 of 31Major et al. BioMed Eng OnLine          (2018) 17:169 
The pressure releases are crucial to eliminate respired  CO2 out of the lung. Thus, 
patients that have hypercapnia should be ventilated with more frequent or longer dura-
tion releases, whereas patients that have hypoxemia require fewer and shorter releases 
requiring patient-specific adjustment [167]. The balancing point has yet to be deter-
mined in groups where both hypoxemia and hypercapnia occur together. APRV facili-
tates spontaneous breathing and has been associated with progressive recruitment [168], 
improved oxygenation [52], reduced peak airway pressures [52, 168], and improved 
volume/flow matching [169] however, a recent review [170] described ‘tremendous 
variation’ in published settings referred to as APRV limiting definitive conclusions and 
clinical application.
Although HFOV and APRV are protective strategies operating on similar principles, 
their applications are quite different. HFOV requires sedation and has not been con-
clusively proven in adult human trials [1, 28]. APRV on the other hand, has been shown 
to be clinically beneficial in spontaneously breathing patients, but is still relatively new 
in practice. Neither is necessarily patient-specific in its application, thus still relying on 
clinical judgement to find optimal settings, and neither has reached a state of regular use 
or wide uptake.
Summary
In summary, it is currently clear that no general, “one size fits all” cohort-specific pro-
tocol is broadly successful. It is equally clear that respiratory failure patients requiring 
mechanical ventilation are highly variable and there is a need to manage mechanical 
ventilation strategy based on patient-specific needs, rather than per cohort. Hence, it 
is very important to have the means to assess the dynamic changes in patient-specific 
respiratory disease state regularly in clinical real-time without additional invasive meas-
urements or interruptions to care. Different strategies, each based upon different intui-
tion on how ventilation can be improved, have been presented. To summarize their 
commonalities and differences, Table 1 briefly summarizes the aims of recent research, 
the driving intuition behind how each strategy intends to address the various problems 
facing MV in clinical practice and the limitations of the strategy. One trend apparent 
in Table 1 is that many recent research areas focus on the related problem of inter- and 
intra-patient variability with the intention that personalized ventilation will avoid VILI 
and enable application to any patient requiring MV without diagnosis of ARDS.
The path forward for mechanical ventilation and the role of engineers
Mechanical ventilation is straightforward in principle. However, it is complex in imple-
mentation, due partly to heterogeneity of disease and partly to the individual’s response 
to treatment. There thus remains a need to improve MV management and engineers 
can play an important role in both research and development of those next-generation 
solutions.
Managing inter‑ and intra‑patient variability
Due to inter- and intra-patient heterogeneity, ventilating respiratory failure patients 
with generalised approaches will not cater for patient-specific needs. What is needed, 
is the ability to accurately assess lung condition non-invasively and in real-time with no 
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interruption to ventilation. In addition, the lung condition of an ARDS or respiratory 
failure patient can change dramatically over the first 24 h of ventilation [171, 172].
In particular, lung condition improves with effective MV, which in turn, can signifi-
cantly alter the patient’s need for subsequent ventilation [60]. Thus, instead of select-
ing PEEP once at the start of MV [7, 9], or only occasionally, ventilation settings should 
be constantly titrated, either breath-to-breath or very regularly. These changes should 
occur in clinical real-time to evolve with the patient and reflect their current condition, 
preferably in an automated fashion that is not burdensome to care givers [173]. How-
ever, this outcome requires automated data acquisition, and computational modelling 
and methods, to provide to necessary monitoring and decision support. More specifi-
cally, automated ventilation strategies that cater for individual, patient-specific needs 
can potentially be realised with the advancement of engineering technologies and 
model-based methods.
Improving technologies and model‑based methods
Lung imaging technologies
Lung imaging is one means of providing regular monitoring of lung condition. Various 
imaging technologies have emerged to help clinicians diagnose patient condition. These 
technologies, such as EIT [174], ultrasound [175–177], or low dose CT [178], provide 
potential means to measure lung condition. These imaging techniques are comparatively 
non-invasive, and can be applied frequently in MV patients to potentially improve MV 
delivery. However, there is significant need for improvement.
For example, EIT operates regionally, capturing lung images representing a 5–10 cm 
cross-section relative to its position [70]. Thus, application of EIT is limited to regional 
lung recruitment monitoring and extrapolation to global measures of ventilation. 
Expanding EIT to multi-slice or complete lung imaging would require a significant 
increase in the number of required sensors, and thus the required computing resource 
for signal processing and image reconstruction, all of which may limit real-time analy-
ses. Significant research is required to optimise the architecture and implementation of a 
real-time, complete lung EIT system, from computational methods to speed solution to 
more advanced and accurate inverse models.
In addition, EIT, CT or ultrasound images do not provide absolute and objective meas-
urement of lung condition. Specialised clinicians are required to interpret images, diag-
nose and recommend treatment. In addition, differences in clinician background and 
experience may potentially lead to inconsistent evaluation, yielding errors in decision-
making and treatment recommendations that may harm patients. Further research is 
required in these existing imaging technologies, including improving image quality, and 
providing more objective information that does not rely on clinical experience and eval-
uation for robust clinical decision-making which, if successful, will ultimately improve 
patient care.
Research in novel ventilation modes
New ventilation modes such as NAVA [179], variable pressure support [151], auto-
matic protective ventilation [173], proportional assist ventilation [180] and other non-
conventional techniques [181] were developed as means to improve MV treatment. 
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Unfortunately, the application of these MV modes remains limited due to a lack of clini-
cal guidelines, based, in turn, on lack of methods to monitor and optimise their use for 
specific patients who might benefit. In addition, there is currently a lack of evidence, 
supported by clinical studies with sufficiently large patient cohorts, to justify application 
of these modern MV modes into daily clinical practice, in turn limiting the data available 
to develop the engineering tools and methods to optimise their use.
Fortunately, these ventilation modes are becoming increasingly popular in engineer-
ing signal processing research. In particular, clinically useful decision support systems 
are being developed to help clinicians interpret patient condition, as well as guide cli-
nicians to better manage MV. For example, Moorhead et  al. studied potential models 
and metrics in setting NAVA level [157], Sinderby et al. have developed a neural index 
to quantify the quality of patient-ventilation interaction during NAVA [182], and Pom-
prapa et al. have investigated lung protective ventilation with the use of EIT [183]. Engi-
neering research was crucial for the development of these MV modes and will continue 
to be critical to their validation and implementation.
Model‑based methods
One prospective topic of MV engineering research relates to applying model-based algo-
rithms in conjunction with specialised clinical protocols. Mathematical modelling of 
the respiratory system, and its effects on the cardiovascular system, allow estimates of 
a patient’s response to changes in their treatment, which can allow virtual trials [184] 
or provide recommendations to a physician as part of a clinical decision support system 
[185].
Mathematical modelling Model-based research can include development of math-
ematical models and validating model relevance, as well as identification of parameters, 
conducting decision metric studies, and clinical trial development. All these outcomes 
also lead toward validating the efficacy and generalizability of physiological models at the 
bedside.
One popular model-based research area is mathematical modelling of lung physiology. 
These models, ranging from simple to complex forms [186–190], describe lung physi-
ology to help researchers better understand lung conditions. Some models can also be 
used to assess real-time patient-specific condition [25, 105, 191–193], recruitment status 
[24, 191, 193, 194], and patient-specific response to MV [191, 193, 195]. Importantly, 
they all offer insight into patient-specific condition that is not available via typical static 
surrogate estimates [189, 196], and, they can be estimated breath-to-breath, and moni-
tored as a surrogate of patient condition without interruption. As a result, they have the 
potential to be applied in MV management [105, 191, 193, 197]. Reviews of lung model-
ling exist [198, 199] but unfortunately, few focus on clinical utility, and none, that we are 
aware of, outside our group [24].
Validation of model‑based methods Mathematical models are typically developed and 
validated with data derived from animal or human studies. An extension of these ‘in-
silico’ simulations is the concept of virtual patients: a dataset of patients, including both 
ventilation and physiologic data, that can be used to test and validate mathematical mod-
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els and their utility to measure disease and provide recommendations. A recent review 
on model-based therapeutics appeared, from our group in this journal, which covered 
modelling of virtual patients and their validation, which is a major step towards using 
models in clinical application to guide care [184].
The natural next step beyond simulation, or virtual patient, based studies are prospec-
tive studies where current ventilation settings and physiologic measurements are used in 
a feedback loop to influence further MV therapy. Several groups have developed meth-
ods to provide ‘automatic’ MV, using physiologic measurements with standard protocols 
or closed-loop feedback systems, to fine-tune ventilator settings during MV however, 
these works are currently limited to animal studies [183, 200]. Similarly, non-model-
based studies have assessed the feasibility of recommending optimal PEEP in small stud-
ies using EIT for example [201]. These studies have shown the feasibility of closing the 
feedback loop to provide near autonomous MV within prescribed parameters.
Personalizing MV to account for inter- and intra-patient variability using mathemati-
cal modelling has been described in simulations [185], retrospective comparison stud-
ies [202] or prospective feasibility/pilot studies aiming to provide recommendations 
[105, 203, 204]. One particular group has recently commercialized their physiological 
modelling research into a decision support system however, their published results are 
also limited to small, feasibility studies [205, 206]. To our knowledge, no large, out-
come-focused trial assessing the clinical utility and efficacy of model-based MV has 
been published. Thus, despite the potential of model-based methods to guide care, as 
seen in other areas [184], there are yet to be any clinical trials comparing outcomes of 
a model-based MV intervention, against standard practice, barring the ongoing CURE1 
trial [207], which is recruiting slowly at this time, and the recently initiated CARE2 trial 
in Malaysia (unpublished).
Next steps in model‑based MV Implementation of any automatic or prescriptive MV 
system, model-based or otherwise, must consider the ramifications of MV in a patient-
specific manner. Some ventilated patients develop asynchrony, expiratory flow limita-
tion or negative hemodynamic consequences during MV. Asynchronous (or dyssynchro-
nous) breathing occurs when the MV is mis-matched with the patient’s breathing efforts. 
Improved signal processing may improve robust application of model-based methods 
[208]. Moreover, improved modelling, for example adding EIT signals, may improve align-
ment between the ventilator and the patient by modelling patient efforts. Expiratory flow 
limitation (EFL) is believed to occur when smaller airways constrict during expiration, 
isolating areas of residual high pressure and thus limiting gas exchange [209]. Appropri-
ate MV settings, especially PEEP, for patients with EFL can be very different than typical 
care; improved modelling could aid detection and PEEP titration to deliver appropriate 
patient-specific care [209]. MV intended to be protective can negatively affect hemody-
namics in ARDS patients [1]. Improved modelling of the cardiopulmonary system could 
yield insights into the hemodynamic effects of MV and mitigate the consequences that 
have lead to early stopping of some clinical trials. Biomedical engineers have a valuable 
1 https ://www.anzct r.org.au/Trial /Regis trati on/Trial Revie w.aspx?id=36683 8.
2 https ://www.anzct r.org.au/Trial /Regis trati on/Trial Revie w.aspx?id=37315 7.
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opportunity to advance clinical practice by combining clinical study results and intuition 
with individualized modelling of a complex, interrelated biomedical system.
Overall, mathematical models can generate insight into pulmonary physiology and 
patient-specific ventilation and perfusion in response to ventilator settings. Equally, 
forecasting poor responses can prevent negative clinical outcomes, such as desatura-
tion or lung collapse and thus further improve patient care at the individual level. There 
is thus an emerging capability for clinicians to titrate patient-specific care using such 
computational models developed in collaboration with engineers. Coupled with regu-
lar recruitment and other protective lung strategies, model-based treatment offers the 
opportunity for clinicians to provide patient-specific therapy in a consistent fashion. In 
essence, software services augment the ventilator hardware and ventilator modes to fur-
ther monitor and optimise care.
Finally, model-based MV research is not without challenge. It is often hindered by the 
need of specialised clinical protocols [38, 210–213], results comparison and validation 
[62, 214, 215], data quality, and model identification [190, 212, 216]. Ultimately, the need 
for large randomised controlled trials is a further limitation. As a result, to date, models 
have not yet been used to prospectively guide therapy directly in a larger setting [105, 
197], although pilot trials have been conducted [25, 207, 217]. Hence, the need of engi-
neering methods to improve mechanical ventilation management is imminent and it is 
paramount for engineers to understand clinical aspects of mechanical ventilation and 
potential advancement.
Conclusion
The overall review summarises the clinical state of the art in the research and application 
of MV in an engineering context. In general, existing MV management is general and 
describes a ‘one size fits all’ cohort-based approach that does not address the heteroge-
neity of the ventilated patient lung, nor the inter- and intra-patient variability critically 
ill patients exhibit. It is thus not able to deliver further improvements in clinical out-
comes without a drastic change towards a patient-specific approach that exploits data 
captured non-invasively in real-time.
New technologies and model-based ventilation have been gaining ground in MV 
research. Model-based estimation enables the clinician to evaluate, otherwise unavail-
able, patient-specific lung condition, monitor patient evolution, and, once informed, 
select an optimal MV setting guided by a clinical protocol. Such a development provides 
an individualised, patient-specific or personalised ‘one method fits all’ approach that 
monitors every breath and guides therapy in real-time, including recruitment manoeu-
vre interventions and timing. This model-based approach in particular provides a means 
for engineers and clinicians to collaborate to create personalised next-generation solu-
tions to this significant and costly health care problem, thus improving clinical ability to 
provide safe, effective MV beyond what is possible today.
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